The Link Between High Sensitivity Troponin T Levels and Outcomes Among Patients with Congestive Heart Failure: A
Alireza Abdollahi1, Zohreh Nozarian2, Samaneh Salarvand1
1Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Insights
High-sensitivity cardiac troponin T (hs-cTnT) elevation predicts worse outcomes in congestive heart failure (CHF) patients. Elevated hs-cTnT signifies increased risk for mortality and hospitalization, aiding clinical management.
Area of Science:
- Cardiology
- Biomarkers
- Prognostics
Background:
- High-sensitivity cardiac troponin T (hs-cTnT) is a key biomarker in cardiovascular diseases.
- Congestive heart failure (CHF) management benefits from accurate prognostic indicators.
Purpose of the Study:
- To systematically review and meta-analyze the association between hs-cTnT levels and clinical outcomes in CHF patients.
- To assess the prognostic value of hs-cTnT in predicting mortality and hospitalization in CHF.
Main Methods:
- Comprehensive literature search across multiple databases for relevant studies.
- Inclusion of studies reporting hazard ratios (HRs) or odds ratios (ORs) for mortality and hospitalization.
- Meta-analysis to pool data and determine overall associations.
Main Results:
- Elevated hs-cTnT showed significant associations with adverse outcomes.
- Pooled HR for all-cause mortality: 1.70; pooled OR: 6.19.
- Pooled HR for cardiovascular mortality: 1.59; pooled OR: 6.87.
- Pooled HR for cardiovascular hospitalization: 1.56; pooled OR: 4.32.
Conclusions:
- Elevated hs-cTnT levels strongly correlate with increased risk of mortality and hospitalization in CHF.
- hs-cTnT serves as a valuable prognostic biomarker for CHF patient management.
Background & Objective:
High-sensitivity cardiac troponin T (hs-cTnT) has emerged as a critical biomarker in cardiovascular diseases, particularly in congestive heart failure (CHF). This systematic review and meta-analysis aimed to assess the association between hs-cTnT levels and clinical outcomes in patients with CHF.
Methods:
A comprehensive literature search was performed across multiple databases to identify studies evaluating the relationship between hs-cTnT levels and clinical outcomes in CHF. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) for all-cause mortality, cardiovascular mortality, or cardiovascular hospitalization.
Results:
Elevated hs-cTnT levels were significantly associated with adverse outcomes. The pooled HR and OR for all-cause mortality were 1.70 (95% CI, 1.49-1.94) and 6.19 (95% CI, 3.88-9.86), respectively. For cardiovascular mortality, the pooled HR was 1.59 (95% CI, 1.38-1.83) and the pooled OR was 6.87 (95% CI, 3.93-12.01). For cardiovascular hospitalization, the pooled HR was 1.56 (95% CI, 1.42-1.70) and the pooled OR was 4.32 (95% CI, 2.22-8.39).
Conclusion:
Elevated hs-cTnT levels are strongly associated with an increased risk of all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization in patients with CHF. These findings highlight the prognostic value of hs-cTnT in the clinical management of heart failure.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Heart Failure VII: Nursing Interventions
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
01:30Acute Coronary Syndrome I: Introduction